Aduro BioTech, Inc.
(NASDAQ : ADRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.55%89.141.3%$797.85m
AMGNAmgen Inc.
1.08%187.501.2%$644.97m
GILDGilead Sciences, Inc.
0.29%65.740.9%$476.37m
BIIBBiogen Inc.
1.30%325.331.3%$432.61m
ILMNIllumina, Inc.
1.41%301.063.5%$311.78m
REGNRegeneron Pharmaceuticals, Inc.
0.93%422.522.6%$280.54m
VRTXVertex Pharmaceuticals Incorporated
1.48%185.761.9%$246.69m
ALXNAlexion Pharmaceuticals, Inc.
1.71%129.732.0%$214.36m
SRPTSarepta Therapeutics, Inc.
2.52%139.9815.4%$157.00m
AAgilent Technologies, Inc.
0.67%78.411.6%$155.05m
EXASExact Sciences Corporation
10.52%92.0425.3%$150.72m
INCYIncyte Corporation
1.82%84.852.5%$112.02m
ARRYArray BioPharma Inc.
2.33%23.248.2%$111.41m
NBIXNeurocrine Biosciences, Inc.
2.07%78.915.1%$80.47m
EXELExelixis, Inc.
1.41%21.526.4%$79.74m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The firm's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. The company was founded in 2000 and is headquartered in Berkeley, CA.